NCT05986877

A Study of STSA-1201 in Healthy Subjects

A Randomized, Double-blind, Placebo-controlled, Single Ascending-Dose Phase Ia Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STSA-1201 Injection in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This study is a Phase Ia, randomized, double-blind, placebo-controlled, single dose, dose escalation safety, tolerability, and pharmacokinetic study of STSA-1201 injection in healthy subjects. A total of 44 healthy subjects were enrolled in four dosage groups.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	STSA-1201 Subcutaneous injection	Subcutaneous injection
DRUG	Placebo	Subcutaneous injection

Timeline

• Start date: 2023-08-04
• Primary completion: 2024-03-14
• Completion: 2024-03-14
• First posted: 2023-08-14
• Last updated: 2024-06-21

Locations

1 site across 1 country: China